Borregaard and Re-Vana establish a strategic partnership, with the potential agreement valued at over 1 billion US dollars.

Boehringer Ingelheim and Re-Vana Therapeutics announce a strategic collaboration and licensing agreement with the aim of developing a first-in-class sustained-release therapy for eye diseases. Up to three development projects will be conducted annually, with a potential total agreement value exceeding $1 billion upon reaching milestone goals.